CRBP net incomeQ3 2026-$37.75M
CRBP net income was -$37.75M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$23.34M a year earlier. For the full fiscal 2025 it was -$78.54M, compared with -$40.21M in fiscal 2024.
Corbus Pharmaceuticals Holdings Inc. (CRBP) financials
For the twelve months ended Sep 30, 2026, Corbus Pharmaceuticals Holdings Inc. reported -$116.31M of net income.
- Net income, TTM
- -$116.31M
- Free cash flow, TTM
- -$92.39M
- EPS, diluted, TTM
- -$6.02
- Cash
- $30.25M
- Market cap
- $69.9M
FY2016FY2022
FY2016FY2025
FY2016FY2025
CRBP revenue and earnings growth
CRBP EPSQ3 2026-$1.81
CRBP diluted EPS was -$1.81 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$5.90, compared with -$3.68 in fiscal 2024.
CRBP free cash flowQ3 2026-$21.25M
CRBP free cash flow was -$21.25M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$15.55M a year earlier. For the full fiscal 2025 it was -$64.50M, compared with -$41.79M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | $0 | $881.7K | $3.94M | $36.14M | $4.82M | $2.44M | $1.91M |
| Research and development | $70.09M | $32.22M | $31.17M | $16.14M | $36.45M | $98.27M | $89.60M | $48.61M | $26.04M | $15.44M |
| Selling, general and admin | $15.21M | $16.50M | $13.91M | $18.70M | $20.43M | $28.48M | $23.64M | $12.96M | $8.96M | $6.46M |
| Operating income | -$85.31M | -$48.72M | -$45.08M | -$39.84M | -$55.99M | -$122.81M | -$77.10M | -$56.75M | -$32.56M | -$19.99M |
| Interest expense | $0 | $1.87M | $3.86M | - | - | - | - | - | - | - |
| Income tax | $0 | $0 | - | - | - | - | - | - | - | - |
| Net income | -$78.54M | -$40.21M | -$44.60M | -$42.35M | -$45.64M | -$111.27M | -$71.45M | -$55.67M | -$32.42M | -$20.00M |
| EPS, basic | -$5.90 | -$3.68 | -$10.31 | -$10.15 | -$11.15 | -$1.42 | -$1.12 | -$0.98 | -$0.65 | -$0.49 |
| EPS, diluted | -$5.90 | -$3.68 | -$10.31 | -$10.15 | -$11.15 | -$1.42 | -$1.12 | -$0.98 | -$0.65 | -$0.49 |
| Diluted shares | 13.3M | 10.9M | 4.3M | 4.2M | 4.1M | 78.1M | 63.9M | 57.0M | 50.2M | 41.1M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $28.49M | $17.20M | $13.72M | $17.00M | $25.01M | $85.43M | $31.75M | $41.75M | $62.70M | $15.19M |
| Short-term investments | $134.78M | $131.86M | $7.18M | $42.19M | $72.64M | - | - | - | - | - |
| Current assets | $166.95M | $152.98M | $23.55M | $60.18M | $100.20M | $92.07M | $38.15M | $44.24M | $65.50M | $17.40M |
| Total assets | $168.19M | $155.88M | $28.27M | $66.31M | $107.73M | $102.29M | $49.14M | $46.99M | $66.98M | $17.89M |
| Current liabilities | $20.69M | $11.82M | $31.89M | $12.64M | $17.01M | $31.90M | $34.89M | $18.09M | $8.20M | $8.90M |
| Short-term debt | - | - | $15.91M | $2.80M | $3.09M | - | - | - | - | - |
| Long-term debt | - | - | $0 | $15.98M | $15.64M | $18.03M | - | - | - | - |
| Total debt | - | - | $15.91M | $18.78M | $18.73M | $18.03M | - | - | - | $271.8K |
| Total liabilities | $20.69M | $13.45M | $35.18M | $33.32M | $38.62M | $57.02M | $42.98M | $19.47M | $9.19M | $8.97M |
| Shareholders' equity | $147.50M | $142.43M | -$6.91M | $32.99M | $69.11M | $45.27M | $6.16M | $27.52M | $57.78M | $8.92M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$64.49M | -$41.79M | -$36.10M | -$37.54M | -$48.18M | -$99.69M | -$45.72M | -$30.07M | -$27.80M | -$13.57M |
| Capital expenditures | $7.0K | $0 | $0 | $13.4K | $54.2K | $484.5K | $2.74M | $2.30M | $707.4K | $353.0K |
| Free cash flow | -$64.50M | -$41.79M | -$36.10M | -$37.56M | -$48.24M | -$100.17M | -$48.46M | -$32.37M | -$28.50M | -$13.92M |
| Investing cash flow | -$1.64M | -$121.31M | $35.64M | $30.07M | -$73.42M | -$484.5K | -$2.74M | -$2.30M | -$707.4K | -$353.0K |
| Financing cash flow | $77.43M | $166.58M | -$2.82M | -$533.6K | $60.82M | $154.87M | $38.46M | $11.42M | $76.01M | $16.74M |
| Stock-based compensation | $6.29M | $6.14M | $3.47M | $5.72M | $9.48M | $12.46M | $11.98M | $7.61M | $5.69M | $3.16M |
| Depreciation and amortization | $233.0K | $588.0K | $641.0K | $763.0K | $999.8K | $1.12M | $739.4K | $493.9K | $255.7K | $87.7K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | -100.0% | -77.6% | -89.1% | 649.5% | 97.6% | 27.7% | 194.8% |
| Operating margin | - | - | - | - | -6350.1% | -3119.2% | -213.3% | -1176.8% | -1334.4% | -1045.6% |
| Net margin | - | - | - | - | -5176.4% | -2826.1% | -197.7% | -1154.5% | -1328.6% | -1046.3% |
| Free cash flow margin | - | - | - | - | -5471.0% | -2544.2% | -134.1% | -671.2% | -1168.1% | -728.5% |
| Return on equity | -53.2% | -28.2% | - | -128.4% | -66.0% | -245.8% | -1160.4% | -202.3% | -56.1% | -224.2% |
| Return on assets | -46.7% | -25.8% | -157.8% | -63.9% | -42.4% | -108.8% | -145.4% | -118.5% | -48.4% | -111.8% |
| Current ratio | 8.07 | 12.94 | 0.74 | 4.76 | 5.89 | 2.89 | 1.09 | 2.45 | 7.98 | 1.96 |
| Debt to equity | - | - | - | 0.57 | 0.27 | 0.40 | - | - | - | 0.03 |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $34.25M | $31.18M | $19.82M | $18.41M | $20.86M | $15.19M | $15.64M | $8.79M | $10.81M | $6.87M | $5.76M | $6.98M |
| Selling, general and admin | $4.58M | $5.01M | $4.49M | $3.56M | $3.56M | $3.96M | $4.13M | $3.82M | $4.70M | $4.12M | $3.86M | $3.12M |
| Operating income | -$38.82M | -$36.19M | -$24.30M | -$21.97M | -$24.42M | -$19.15M | -$19.77M | -$12.61M | -$15.51M | -$10.99M | -$9.62M | -$10.10M |
| Interest expense | - | - | - | $0 | $0 | $0 | $0 | $0 | $381.0K | $652.0K | $839.0K | $930.0K |
| Net income | -$37.75M | -$35.04M | -$22.97M | -$20.55M | -$23.34M | -$17.66M | -$16.98M | -$9.53M | -$13.78M | -$10.00M | -$6.90M | -$8.02M |
| EPS, basic | -$1.81 | -$1.81 | -$1.23 | -$1.17 | -$1.90 | -$1.44 | -$1.39 | - | -$1.15 | -$0.90 | -$0.83 | -$1.75 |
| EPS, diluted | -$1.81 | -$1.81 | -$1.23 | -$1.17 | -$1.90 | -$1.44 | -$1.39 | - | -$1.15 | -$0.90 | -$0.83 | -$1.75 |
| Diluted shares | 20.8M | 19.4M | 18.7M | - | 12.3M | 12.2M | 12.2M | - | 12.0M | 11.1M | 8.3M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $30.25M | $23.37M | $25.66M | $28.49M | $26.98M | $20.04M | $18.90M | $17.20M | $19.42M | $23.69M | $14.10M | $13.72M |
| Short-term investments | $85.09M | $94.57M | $112.56M | $134.78M | $77.00M | $96.55M | $113.89M | $131.86M | $139.94M | $123.34M | $106.00M | $7.18M |
| Current assets | $118.95M | $122.75M | $143.57M | $166.95M | $107.57M | $122.83M | $137.36M | $152.98M | $160.89M | $148.31M | $121.70M | $23.55M |
| Total assets | $122.90M | $126.99M | $144.48M | $168.19M | $109.51M | $125.08M | $139.93M | $155.88M | $164.17M | $151.98M | $125.74M | $28.27M |
| Current liabilities | $34.97M | $21.48M | $18.14M | $20.69M | $17.06M | $13.33M | $11.62M | $11.82M | $11.63M | $23.98M | $25.92M | $31.89M |
| Short-term debt | - | - | - | - | - | - | - | - | - | - | $12.76M | $15.91M |
| Long-term debt | - | - | - | - | - | - | - | - | - | - | $0 | $0 |
| Total debt | - | - | - | - | - | - | - | - | - | - | $12.76M | $15.91M |
| Total liabilities | $38.14M | $24.75M | $18.14M | $20.69M | $17.37M | $14.09M | $12.82M | $13.45M | $13.67M | $26.44M | $28.78M | $35.18M |
| Shareholders' equity | $84.76M | $102.24M | $126.34M | $147.50M | $92.15M | $110.99M | $127.11M | $142.43M | $150.50M | $125.54M | $96.97M | -$6.91M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$21.24M | -$29.63M | -$25.57M | -$15.92M | -$15.55M | -$16.60M | -$16.42M | -$10.94M | -$13.94M | -$8.94M | -$7.97M | -$6.01M |
| Capital expenditures | $15.0K | $6.0K | $6.0K | $7.0K | $0 | $0 | $0 | - | - | - | - | $0 |
| Free cash flow | -$21.25M | -$29.63M | -$25.58M | -$15.93M | -$15.55M | -$16.60M | -$16.42M | - | - | - | - | -$6.01M |
| Investing cash flow | $9.56M | $18.26M | $22.45M | -$57.15M | $19.64M | $17.74M | $18.12M | $8.73M | -$15.37M | -$16.44M | -$98.24M | $10.39M |
| Financing cash flow | $18.55M | - | - | $74.58M | $2.85M | $0 | $0 | -$13.0K | $25.04M | $34.97M | $106.58M | -$1.91M |
| Stock-based compensation | $1.81M | $1.81M | $1.92M | $1.43M | $1.58M | $1.56M | $1.71M | $1.63M | $2.24M | $1.29M | $982.0K | $799.0K |
| Depreciation and amortization | $50.0K | $51.0K | $49.0K | $49.0K | $50.0K | $53.0K | $81.0K | $134.0K | $152.0K | $150.0K | $152.0K | $148.0K |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 3.40 | 5.71 | 7.92 | 8.07 | 6.31 | 9.21 | 11.82 | 12.94 | 13.84 | 6.18 | 4.69 | 0.74 |
| Debt to equity | - | - | - | - | - | - | - | - | - | - | 0.13 | - |
Source: XBRL data Corbus Pharmaceuticals Holdings Inc. files with the SEC, latest filing dated Nov 10, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
CRBP peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| CRBP | - | - | -$116.31M | - | $69.9M |
| KNSA | $945.96M | +58.2% | $109.57M | 11.6% | $7.57B |
| VRDN | $26.31M | -62.8% | -$453.58M | -1724.1% | $3.51B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $59.58B |
| KYTX | - | - | -$157.79M | - | $319.3M |
| CABA | - | - | -$189.50M | - | $276.1M |
CRBP FAQ
6 questionsIs CRBP profitable?
No. Corbus Pharmaceuticals Holdings Inc. reported a net loss of $116.31M for the twelve months ended Sep 30, 2026.How much cash and debt does CRBP have?
Corbus Pharmaceuticals Holdings Inc. reported $30.25M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is CRBP free cash flow?
Corbus Pharmaceuticals Holdings Inc. generated -$92.39M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$92.36M less capital expenditures.What is CRBP earnings per share?
Diluted earnings per share were -$6.02 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.When did CRBP last report financial results?
The latest statements here come from Corbus Pharmaceuticals Holdings Inc.'s 10-Q filed on Nov 10, 2026, covering the period ended Sep 30, 2026.Where does this CRBP financial data come from?
Quantisnow builds these statements from the structured XBRL data Corbus Pharmaceuticals Holdings Inc. files with the SEC. It is provided for information only and is not investment advice.